Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): Enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)

CNS Spectrums

Volumn 20, Issue 2, 2015, Pages 93-97

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND GATED ION CHANNEL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN TRANSPORTER; VORTIOXETINE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SULFIDE;

ARTICLE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; NERVE CELL NETWORK; PRIORITY JOURNAL; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; ANIMAL; DRUG EFFECTS; HUMAN; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; PIPERAZINES; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN RECEPTOR AGONISTS; SULFIDES;

EID: 84926383738     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000139     Document Type: Article

References (28)

1. Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013; 18(3): 113-117.
2. th ed. Cambridge, UK: Cambridge University Press; 2013.
3. Zohar J, Stahl S, Moller H-J, et al. Neuroscience Based Nomenclature. Cambridge, UK: Cambridge University Press; 2014.
4. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012; 340(3): 666-675.
5. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment ofmajor depressive disorder. J Med Chem. 2011; 54(9): 3206-3221.
6. Areberg J, Luntang-Jensen M, Søgaard B, Nilausen DØ. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012; 110(4): 401-404.
7. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multi-modal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma-aminobutyric acid) release by blocking 5HT3 and 5HT7 receptors. CNS Spectr. In press.
8. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multi-modal agent (MMA): enhancing downstream release of neurotransmitters by blocking 5HT3 receptors. CNS Spectr. In press.
9. Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multi-modal agent (MMA): enhancing downstream release of four pro-cognitive neurotransmitters by blocking 5HT1D receptors. CNS Spectr. In press.
10. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7): 748-751.
11. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19(2): 121-133.
12. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013; 23(2): 133-145.
13. Fink KB, Gothert M. 5HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007; 59(4): 360-417.
14. Assié MB, Lomentach H, Ravailhe V, Faucillon V, Newman-Tancredi A. Rapid desensitization of somatodendritic 5HT1A receptors by chronic administration of the high-ef ficacy 5HT1A agonist, F13714: a microdialysis study in the rat. Br J Pharmacol. 2006; 149(2): 170-178.
15. Gardier AM, Malgie I, Trillat AC, Jacquot C, Artigas F. Role of 5HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol. 1996; 10(1): 16-27.
16. Romero L, Ben N, Artigas F, De Montigny C, Blier P. Effect of pindolol on the function of pre- and postsynaptic 5HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 1996; 15(4): 349-360.
17. Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5HT1A and 5HT1B agonists. Synapse. 1987; 1(1): 3-9.
18. Adell A, Celada P, Artigas F. The role of 5HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem. 2001; 79(1): 172-182.
19. De Groote L, Klompmakers AA, Olivier B, Westenberg HG. Role of extracellular serotonin levels in the effect of 5HT1B receptor blockade. Psychopharmacology (Berl). 2003; 167(2): 153-158.
20. Ruf BM, Bhagwagar Z. The 5HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009; 10(11): 1118-1138.
21. Sari Y. Serotonin 1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004; 28(6): 565-582.
22. Sarkisyan G, Roberts AJ, Hedlund PB. The 5HT7 receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res. 2010; 209(1): 99-108.
23. Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5HT)7 receptors enhances 5HT neurotransmission, antidepressant-like behavior and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007; 321(2): 690-698.
24. Stenkrona P, Halldin C, Lundberg J. 5HTT and 5HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013; 23(10): 1190-1198.
25. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neuosci. 2007; 32(2): 86-102.
26. Lundberg J, Tiger M, Landén M, Halldin C, Farde L. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(8): 1167-1172.
27. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an 11C-DASB positron emission tomography study. Am J Psychiatry. 2004; 161(5): 826-835.
28. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014; 68(1): 60-82.